MINNEAPOLIS, April 08, 2016 -- On March 3, 2016, Vascular Solutions, Inc., (Nasdaq:VASC) initiated a nationwide recall of Guardian II hemostasis valves used in catheterization procedures. Specific lots of the products have been recalled because they pose an increased risk of air leakage that may lead to an air embolism, which could result in serious injury or death. This recall only affects the Guardian II hemostasis valves and does not include the Guardian II NC hemostasis valves. No injuries have been reported in association with this issue to date.
Healthcare facilities that have the affected Guardian II hemostasis valves should remove the products from their inventory and return them to Vascular Solutions.
The recalled products were manufactured from March 2015 to February 2016 and distributed from April 2015 to February 2016.
The recalled products are specific lots of Model Numbers 8210 and 8211. A listing of the recalled lots is available from Vascular Solutions and has been provided to each facility that purchased the affected products. A total of 26,550 devices have been manufactured, with 5,283 distributed in the United States. The condition that led to the recall may affect approximately 2.4% of recalled devices.
Vascular Solutions Inc. voluntarily initiated the recall on March 3, 2016 through an Urgent Medical Device Recall notification distributed to purchasers of the affected products. The notification identified the specific lots subject to the recall and included instructions on how to return the affected products.
The U.S. Food and Drug Administration (FDA) classified this as a Class I recall. FDA defines Class I recalls as “a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.”
Consumers with questions may contact the company by phone at 1-888-240-6001 Monday through Friday, between the hours of 8:00 a.m. and 5:00 p.m. Central Time or by email at [email protected]. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program:
- Online at http://www.fda.gov/medwatch/report.htm
(form available to fax (1-800-FDA-0178) or mail), or - Call FDA 1-800-FDA-1088 to request a reporting form
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of more than 90 products and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.
For further information, connect to www.vasc.com.
Contact: Phil Nalbone VP of Corporate Development Vascular Solutions, Inc. (763) 656-4371


Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
xAI Cash Burn Highlights the High Cost of Competing in Generative AI
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 



